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Atopic dermatitis and psoriasis are the two most common immune-mediated inflammatory disorders affecting the skin. Genome-wide
studies demonstrate a high degree of genetic overlap, but these diseases have mutually exclusive clinical phenotypes and opposing im-
mune mechanisms. Despite their prevalence, atopic dermatitis and psoriasis very rarely co-occur within one individual. By utilizing
genome-wide association study and ImmunoChip data from >19,000 individuals and methodologies developed from meta-analysis,
we have identified opposing risk alleles at shared loci as well as independent disease-specific loci within the epidermal differentiation
complex (chromosome 1q21.3), the Th2 locus control region (chromosome 5q31.1), and the major histocompatibility complex (chro-
mosome 6p21–22). We further identified previously unreported pleiotropic alleles with opposing effects on atopic dermatitis and pso-
riasis risk in PRKRA and ANXA6/TNIP1. In contrast, there was no evidence for shared loci with effects operating in the same direction on
both diseases. Our results show that atopic dermatitis and psoriasis have distinct genetic mechanisms with opposing effects in shared
pathways influencing epidermal differentiation and immune response. The statistical analysis methods developed in the conduct of
this study have produced additional insight from previously published data sets. The approach is likely to be applicable to the investi-
gation of the genetic basis of other complex traits with overlapping and distinct clinical features.Introduction
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Despite a lifetime prevalence of ~2% for psoriasis and
10%–20% for AD,3,4 these diseases rarely co-occur within
an individual5—an observation attributed to opposing im-
mune response patterns.6 However, it has been reported
that both Th1-cell-dominated autoimmune and Th2-cell-
dominated allergic diseases aggregate within families7
and that parental psoriasis might increase the risk of AD
in offspring.8 Furthermore, genome-wide linkage and asso-
ciation studies have shown genetic risk loci in each disease
that map to similar regions of the genome. The epidermal
differentiation complex (EDC) on chromosome 1q21.3 in-
cludes AD and psoriasis risk loci in close proximity.9–12
Null mutations in the gene encoding filaggrin (FLG [MIM
135940]) represent the strongest known risk factor for
AD13,14 and account for at least a proportion of AD risk
within the EDC, but FLG-null mutations are not associated
with psoriasis.15,16 A deletion of the late cornified envelope
genes LCE3B-LCE3C (MIM 612614, 612615) represents a
genetic substrate for psoriasis within the EDC,17,18 but
this deletion is not associated with AD.19 The cytokine
cluster encoded at 5q23.1–5q31.1 includes variants
showing association with both diseases,10,20,21 and an in-
tergenic region of chromosome 20q13.2 has also shown as-
sociation with both AD and psoriasis.22,23 Finally, a recent
genome-wide association study (GWAS) on AD identified a
strong association within the margins of the major histo-
compatibility complex (MHC)20 on chromosome 6p21.3,
less than 2.4 kb from a variant associated with HLA-Cw6
(MIM 142840),24 the strongest known psoriasis-risk locus.
In order to gain insight into overlapping and specific
genetic mechanisms, we systematically compared and con-
trasted AD and psoriasis via analytical techniques devel-
oped from meta-analysis.Subjects and Methods
Study Subjects
Genome-wide genotype data were obtained on samples from six
case-control cohorts (three each of AD and psoriasis), totaling
2,262 AD and 4,489 psoriasis case subjects and 12,333 control sub-
jects (Table S1 available online).
The German AD case subjects were recruited from tertiary
dermatology clinics at Munich, as part of the GENEVA study, Uni-
versity of Kiel, University of Bonn, and the University Children’s
Hospital of Charite´ Universita¨tsmedizin Berlin. AD was diagnosed
by experienced dermatologists and/or pediatricians according to
the UK Diagnostic Criteria.25 German control subjects were ob-
tained from the PopGen biorepository,26 the population-based
KORA study in southern Germany,27 and the German part of
ISAAC II to assess the prevalence of asthma and allergies in school-
children.28 The Irish AD case collection was recruited from the sec-
ondary and tertiary pediatric dermatology clinic at Our Lady’s
Children’s Hospital, Crumlin, Dublin. Irish control individuals
were obtained from healthy adult blood donors as part of the
Trinity Biobank, Dublin.29
The German psoriasis case subjects were recruited from the ter-
tiary dermatology clinic at the University of Kiel and German con-
trols were again obtained from the PopGen biorepository and theThe AmerKORA study (independent from those used as controls for AD).
The British psoriasis case-control study is part of the Welcome
Trust Case Control Consortium 224 and the US psoriasis study
has been described elsewhere.21
ImmunoChip data on 2,425 AD case subjects, 3,580 psoriasis
case subjects, and 9,061 control subjects were obtained from pre-
vious studies,11,12 including data on a subset of case and control in-
dividuals also analyzed by GWAS. Results of analysis of the four
most prevalent FLG (RefSeq accession number NM_002016.1)
loss-of-function mutations were obtained for a total of 2,865 case
subjects and 5,540 control subjects as data generated for previous
studies;11,20 the FLG mutations in these analyses are as follows:
p.Arg501* (c.1501C>T), p.Ser761Cysfs*36 (c.2282_2285del),
p.Arg2447* (c.7339C>T), and p.Ser3247* (c.9740C>A) (R501X,
2282del4, R2447X, and S3247X, respectively).
The institutional review board in each contributing center
approved these studies. All participants (or their parents or guard-
ians) gave written informed consent.Study Design
The study design is summarized in Figure 1.Quality Control
Quality control and standard GWAS analysis of genotyped single-
nucleotide variants (SNVs) was carried out with PLINK30 and R.
Samples with extensive missing data (rate >5%), excess of hetero-
zygosity or homozygosity, and discrepant gender determined on
the basis of average X-chromosomal heterozygosity compared to
the gender recorded in the database were excluded.We then exam-
ined identity-by-state (IBS) sharing and estimated identity-by-
decent (IBD) on a pruned SNV set between all pairs of individuals
and deleted resulting duplicates or closely related samples with
PI_HAT > 0.1875 (halfway between expected IBD for third- and
second-degree relatives). Multidimensional scaling (MDS) of the
pairwise IBS matrix was carried out to identify and delete outliers
of unusual ancestry and to calculate genome-wide principal-
component scores for each individual. We excluded 894 samples
because of SNVs showing a missing rate of >5%, deviation of
Hardy-Weinberg equilibrium pHWE < 10
8, or minor allele fre-
quency (MAF) <5% (summarized in Table S2). After quality con-
trol, the resulting SNVs and samples were analyzed for association
via logistic regression with age, sex, and principal-component
scores as covariates. Results from each panel were investigated to
determine whether established GWAS loci were identified for the
respective trait of interest, and genomic control inflation factors
were calculated.Imputation of SNVs and Classical HLA Alleles
Any SNVs showing significant association were checked (e.g., by
visual inspection of the intensity cluster plots and investigation
of consistency of LD with surrounding markers) and those SNVs
deemed unreliable were removed. The final data sets of high-qual-
ity SNVs were prephased with SHAPEIT31 and subsequently used
to perform imputation with IMPUTE2,32 the 1000 Genomes refer-
ence panel (integrated variant set, release March 2012).33 In the
Irish AD collection (Table S1), case and control subjects were gen-
otyped on different platforms, and therefore only the 131,692
SNVs in common between the platforms were used to inform
imputation.
Postimputation SNVs with low imputation quality (info score <
0.4), call rate <95%, deviation from pHWE < 10
8, or MAF < 5%ican Journal of Human Genetics 96, 104–120, January 8, 2015 105
Figure 1. Study Design
Abbreviations are as follows: CCMA, case
control meta-analysis; MANTRA, meta-
analysis of trans-ethnic association studies;
BFD, Bayesian false discovery; PO, prior
odds; *conditional analysis for the MHC
was also carried out with imputed classical
HLA-allele (detailed in the Subjects and
Methods).were excluded. A final data set of approximately 5.2 million SNVs
in 2,079 AD case subjects, 3,867 control subjects, 4,212 psoriasis
case subjects, and 8,032 control subjects were eligible for subse-
quent analysis (Table S3).
Classical alleles for HLA-A, HLA-B, and HLA-C were imputed for
each case-control cohort separately by HLA*IMP34,35 and best
guess genotypes with probability >0.9. Additional classical HLA-
DQA1, HLA-DQB1, and HLA-DRB1 alleles were imputed in each
case-control cohort with the exception of the Irish samples, in
which there were insufficient informative SNPs. Alleles with a fre-
quency>1%were put forward for analysis. For each individual, al-
leles were coded as having no, one, or two copies of the respective
allele via allele probability >0.9. We obtained high-quality data at
the four-digit level with call rates of 92%–100% and accuracy of
92%–98%.
Statistical Analysis
Meta-GWAS was performed on each disease, via standard method-
ologies. To analyze these findings further, we developed two
different meta-analysis-based approaches to filter SNVs andmodel
the contrasting effects in each disease. The first was a compare and
contrast meta-analysis (CCMA) approach inspired by a subset-
based method.36 The second used transethnic meta-analysis im-
plemented in the MANTRA software,37 combining all six studies
by using prior clustering to reflect the ethnic difference and the
disease type. The MHC region was reserved for separate analysis
because of its unique and complex variability and patterns of
strong linkage disequilibrium (LD).
The CCMA approach is based on an adaptation of an idea of
Bhattacharjee et al.,36 who modeled association with heteroge-
neous traits. With METAL,38 we calculated z-scores signed positive
or negative with respect to the same reference allele for two meta-
analyses, T1, combining AD studies only, and T2, combining pso-
riasis studies only. We then calculated the overall test statistic Tmax
with the formula Tmax ¼maxðjT1j; jT2j; jT12sharedj;

T12opposing

Þ,
where T12shared ¼ ðT1 þ T2Þ=
ﬃﬃﬃ
2
p
and T12opposing ¼ ðT1  T2Þ=
ﬃﬃﬃ
2
p
. We
categorized the effect of each SNV as corresponding to an effect106 The American Journal of Human Genetics 96, 104–120, January 8, 2015on AD only, to an effect on psoriasis
only, to a shared effect (in the same di-
rection on AD and psoriasis), or to op-
posing effects, according to which of the
four test statistics ðjT1j; jT2j; jT12shared j;

T12opposing

Þ was the largest. In order to
derive a p value for Tmax, we worked out
an empirical null distribution by simu-
lating 10,000,000 realizations of two nor-
mally distributed random variables, Z1
and Z2. Then we calculated Z12shared ¼
ðZ1 þ Z2Þ=
ﬃﬃﬃ
2
p
, Z12opposing ¼ ðZ1  Z2Þ=
ﬃﬃﬃ
2
p
,
and Zmax ¼maxðjZ1j; jZ2j; jZ12shared j;

Z12opposing

Þ. The emprical p values can be derived as
Pemp ¼ ð#ðZmax > TmaxÞ þ 1Þ=ð# simulationsþ 1Þ.
In a separate simulation of 1,000,000,000 replicates, we derived
a calibration curve for the p values and found it suitable up to a p
value of 109. Hence with the calibration curve we can derive Zmax
thresholds corresponding to standard genome-wide ‘‘suggestive’’
(105) and genome-wide ‘‘significant’’ (108) thresholds, corre-
sponding to Tmax values of approximately 4.7 and 6.0, respectively
(Figure S1).
In the second approach we used the MANTRA software37 devel-
oped for transethnic meta-analysis. MANTRA uses a Bayesian
partition model for grouping studies according to their ethnicity.
We adopted this idea and worked out a prior distribution to cluster
studies according to both our phenotypes of interest and the ge-
netic distance between the studies derived from our MDS analysis
based on the pairwise IBSmatrix:DTotal¼DDiseaseþDEthnicity, where
DEthnicity is a diagonal matrix of Euclidean distances between study
centers. To distinguish the two diseases (psoriasis and AD),
we set the corresponding cells of the DDisease matrix to Dij ¼ 2 3
max(DEthnicity) and to account for the different subphenotype in
AD (AD in general versus childhood AD), we set the corresponding
cells of the DDisease matrix to Dij ¼ max(DEthnicity), resulting in the
prior components shown in Table S4.
We calibrated the resulting log10BFMANTRA¼ log10(Bayes Factors)
from the MANTRA software in order to find a threshold for
filtering SNVs, which were compared with the CCMA top SNVs
and subsequently carried forward to multinomial regression
modeling. To perform this calibration, we calculated the Bayesian
False Discovery Probability proposed by Wakefield39 with diverse
prior odds (PO) in favor of H0:
BFDP ¼ BFMANTRA3PO
1þ BFMANTRA3PO:
Sensitivity analysis was performed with only the DEthnicity as prior
matrix and we observe high correlation (r2 > 0.99) of the top-
ranked SNVs (BFDP < 0.05; PO ¼ 99) with our analysis (data not
shown).
Finally, we carried forward a filtered set of SNVs fromCCMA and
MANTRA for modeling via a multinomial regression model,
adjusted for sex and the first four genome-wide principal-com-
ponent scores. The multinomial model involves three outcome
categories: the ‘‘baseline’’ category into which all controls are cate-
gorized, a ‘‘psoriasis’’ case category, and an ‘‘AD’’ case category
(modeled through regression coefficients bPSO and bAD, respec-
tively). This analysis makes use of individual-level genotypes and
is thus more computationally intensive (although arguably more
powerful and more statistically satisfactory) than CCMA and
MANTRA. We calculated p values for tests that were designed to
be sensitive to the following situations: an overall SNV effect (on
either or both diseases, in either direction), an individual SNV ef-
fect on one disease (but not on the other), a shared SNV effect
(operating in the same direction for both diseases), and a contrast-
ing SNVeffect (operating in opposing directions between both dis-
eases), by performing Wald tests of the following linear
hypotheses:
Overall effect : H0 :
bPSO þ bAD
bPSO  bAD ¼
0
0
; H1 :
bPSO þ bAD
bPSO  bADs
0
0
Psoriasis effect : H0 : bPSO ¼ 0; H1 : bPSOs0
AD effect : H0 : bAD ¼ 0; H1 : bADs0
Shared effect : H0 : bPSO þ bAD ¼ 0; H1 : bPSO þ bADs0
Opposing effect : H0 : bPSO  bAD ¼ 0; H1 : bPSO  bADs0
The overall significance of the SNV was assessed through the 2
degree of freedom (df) test of overall effect, which compares the
null hypothesis that the SNV has no effect on either psoriasis or
AD with the alternative hypothesis that it has an effect on one
or both diseases. The other four 1 df tests were used to categorize
the effect (in analogy to CCMA) in four categories—AD only, pso-
riasis only, shared effect, and opposing effects—by categorizing ac-
cording to the minimum of the p values: pMNM ¼ min(pAD, pPSO,
pSHARED, pOPPOSING). The rationale for the use of the minimum
of these 1 df tests for categorization is as follows: if a SNV is asso-
ciated with one disease but not the other, the test of a nonzero
regression coefficient for that disease (even while unnecessarily
also allowing for a nonzero coefficient for the other disease, as is
done in the psoriasis effect and AD effect tests), should be more
powerful than a test that erroneously groups together the coeffi-
cients of the associated and the nonassociated disease (as is done
in the shared and opposing effect tests). This is on account of
the fact that grouping together these coefficients will incur a pen-
alty in terms of increasing the variance, while not incurring any
greater expected magnitude of effect since the expected value of
the regression coefficient for the nonassociated disease is zero. If,
on the other hand, the SNV has effects that operate in the same
direction on both diseases, then a test based on adding together
these effects (as is done in the shared effect test) should be more
powerful than considering each effect on its own, or subtracting
one effect from the other (as is done in the opposing effect test),
because adding together the coefficients induces the greatest
magnitude of effect. Finally, if the SNV has effects that operate
in opposite directions in the two diseases, then a test based on sub-
tracting one effect from the other (as is done in the opposing effect
test) should be most powerful because it induces the greatest
magnitude of effect.The AmerAll analyses if not explicitly stated were carried out with R. For
the purposes of this analysis, we distinguished between a shared
genetic ‘‘region’’ and a shared genetic ‘‘locus.’’ We arbitrarily desig-
nated a shared region as a block of genomic DNA spanning 2 Mb
with association signals for both traits. We defined a genetic locus
as the lead SNV and all SNVs with r2 > 0.5.
Predicted Protein Network Analysis and Gene
Ontology Analysis
Functional protein association networks were investigated in silico
and gene ontology analyses were performed with STRING9.1.Results
Filtering Variants to Define Risk Effects
Quality control and imputation generated 5.2 million
SNVs with a minor allele frequency >0.01 for further anal-
ysis (Figure 1). GWASs within each cohort resulted in
genomic inflation factors l between 1.03 and 1.08. Meta-
GWAS performed on each disease confirmed previously
reported risk loci in AD and psoriasis and illustrated areas
of colocalization on chromosomes 1, 5, and 6 (Figure 2A).
Excluding the MHC, 2,210 SNVs were identified with
shared (by which we mean alleles having effects operating
in the same direction in both diseases), opposing, and dis-
ease-specific SNVs with CCMA test statistic Tmax> 4.7. This
threshold was defined to correspond to a suggestive signif-
icance of p< 105 in order to reduce the probability of false
negatives. The 2,210 SNVs were condensed to 142 distinct
loci after an LD-based clumping procedure30 with the
following parameters: distance % 250 kb and r2R 0.5.
Analysis with MANTRA revealed 3,304 SNVs with
Bayesian false discovery probability (BFDP) < 0.05 with
prior odds (PO) 1/99 resulting in 76 distinct loci after
clumping. The overlap of CCMA and MANTRA gave
2,183 SNVs and the union of both methods resulted in
3,331 SNVs that were carried forward for multinomial
regression modeling (MNM), which was adjusted for sex
and the first four genome-wide principal-component
scores. The results are displayed in Figure 2B, in which dis-
ease-specific, shared, and opposing loci are coded by color.
SNVs showing genome-wide significance in at least one of
the three methods of analysis (Tmax > 6, BFDP < 0.05 with
PO ¼ 1/999, or pMNM < 108) map to 144 distinct loci (Ta-
ble S5). Comparison of effect classification (AD, psoriasis,
shared, opposing) in CCMA and MNM (Figure S2) showed
an agreement of 94.8% when excluding the MHC region
(Figure S3). For further investigation, we considered only
loci containing more than one SNV and an effect classified
in the same direction by CCMA and MNM.
Validation of Previously Reported AD- and
Psoriasis-Risk Loci
15 European and 9 Asian loci have previously been re-
ported in GWASs on AD, and 44 European and 9 Asian
loci have been reported in association with psoriasis (Table
S6). In our disease-specific meta-analysis individuals ofican Journal of Human Genetics 96, 104–120, January 8, 2015 107
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Figure 2. Genome-wide Comparison of
AD and Psoriasis
(A) Mirrored Manhattan plots showing re-
sults of AD meta-GWAS (top) and psoriasis
meta-GWAS (bottom).
(B) Comparative analysis of AD and psoria-
sis in which SNVs are color coded to show
AD-specific effect (black), psoriasis-specific
effect (red), shared effects defined as alleles
operating in the same direction (green),
and opposing effects (blue). The genome-
wide significance level is marked at p ¼
0.5 3 108 (Tmax ¼ 6.0).white European descent, 14 of the European AD loci as well
as 43 of the psoriasis loci are replicated. Furthermore, 4 AD
and 4 psoriasis loci so far reported only in Asians showed
evidence for association in European populations (p <
103): CCDC80 (MIM 608298)/CD200R1L at 3q13.2,
CARD11 (MIM 607210) at 7p22.2, ZNF365 (MIM
607818) at 10q21.2, and BCAS1 (MIM 602968) at
20q13.2 in AD;CSMD1 (MIM 608397) at 8p23.2, SERPINB8
(MIM 601697) at 18q22.1,MAMSTR (MIM 610349)/RASIP1
(MIM 609623) at 19q13.33, and ZNF816A at 19q13.41 in
psoriasis (Table S6).
New Opposing-Effect Loci Identified by Genome-wide
Comparative Analysis
Excluding the MHC, 25 loci showed a genome-wide sig-
nificant association with either skin disorder, defined
by all three methods of analysis (CCMA Tmax > 6 and
MANTRA BFDP < 0.05 with PO ¼ 1/999, and pMNM <
108) including six loci that were coassociated with both
AD and psoriasis. Each coassociated locus displayed
opposing effects and two of these loci (2q31.2, 5q33.1)
have not previously been reported as showing coassocia-
tion with AD and psoriasis (Table 1).
2q31.2 demonstrates an opposing effect at rs62176107
(MNM p ¼ 1.08 3 1034; Table S5); this variant is within
exon 6 of PRKRA (MIM 603424) and also within
microRNA 548n (MIR548N) and a noncoding transcript,
AC009948.5. PRKRA encodes protein kinase interferon-
inducible double-stranded RNA-dependent activator
(PACT), a cellular dsRNA-binding protein originally identi-
fied as a binding partner and activator of PKR in response
to extracellular stress.46 More recently, it has been shown
to be an essential factor in the PKR-independent initiation108 The American Journal of Human Genetics 96, 104–120, January 8, 2015of RIG-I-induced antiviral response.47
Of note, individuals with AD are
known to be susceptible to viral skin
infections, but cutaneous infec-
tions rarely occur in psoriasis.48
MicroRNAs play a role in posttran-
scriptional regulation of gene expres-
sion by affecting the stability and
translation of mRNAs, but the specific
role of miRNA548n has not been
defined. Themost significantly associ-ated (‘‘lead’’) SNV at 2q31.2 (rs62176107, G>A, having the
smallest p value from MNM) is a synonymous SNV with
predicted effects on 12 transcripts, including PRKRA splice
variants’ UTR and intronic regions and a variant predicted
to undergo nonsense-mediated decay (Ensembl release 75).
Gene expression profiling data show downregulation of
both PRKRA mRNA and miRNA548n in psoriatic lesions
compared to nonlesional skin, but no significant differ-
ences in AD (Table S7).
The most highly significant variant at 5q33.1
(rs17728338) shows opposing effects on AD and psoriasis
(MNM p ¼ 3.96 3 1038; Table S5) and lies 2 kb upstream
of ANXA6 (MIM 114070) and 8 kb downstream of TNIP1
(MIM 607714). LD analysis in 1000 Genomes (release
August 2009) via LocusZoom49 showed that rs17728338
is located within a 25-kb block containing both TNIP1
and ANXA6. The locus has previously been associated
with psoriasis in European and Chinese populations
but has not been implicated in AD. TNIP1 is involved in
TNF signaling and regulation of the transcription factor
NF-kB;21,50 it shows increased expression both in AD and
psoriatic lesions compared to control skin (Table S7). In
contrast, ANXA6, which encodes a calcium-dependent
membrane and phospholipid binding protein, shows
significant upregulation of expression in atopic skin
compared to control skin (fold change 1.3, FDR p ¼
0.016) and lesional to nonlesional AD skin (fold change
2.4, p ¼ 0.027), whereas expression is decreased in psori-
atic versus healthy skin (fold change 0.7, p ¼ 6.38 3
1013) (Table S7). Clearly, further finemapping is necessary
to identify the causal variant that exerts opposing effects
on AD and psoriasis, but we speculate that ANXA6 might
be a switch-point differentiating AD from psoriasis that
Table 1. Loci Showing Genome-wide Significant Association with Either AD or Psoriasis Defined by All Three Methods of Comparative Analysis
Chr Band
Reference SNV
Number(s) Position (hg19) Nearest Gene(s) or Transcript(s)
Effect Observed
in GW Analyses
Estimated Odds Ratio (95% CI)
Previous Report(s) of Association at
This LocusAD Psoriasis
1p31.3 rs77614545 (del) 67749581 retro-DNAJB6 and IL23R (MIM 607562) psoriasis 0.99 (0.92–1.07) 1.21 (1.15–1.28) psoriasis: 1p31.3 locus, IL28RA21,24,40
1q21.3a rs55879323 152168740 within FLG-AS1 opposing 0.76 (0.70–0.82) 1.05 (1.00–1.12) AD and psoriasis: 1q21.3 locus, HRNR,
FLG;41 FLG;20,42 LCE3B, LCE3C,18 LCE
gene cluster;17 LCE3D24
rs11205006,
rs12144049
152440176,
152440910
RP1-91G5.3, CRNN (MIM 611312),
LCE5A (MIM 612619)
AD 1.52 (1.41–1.64),
1.53 (1.42–1.64)
0.97 (0.92–1.03),
0.98 (0.92–1.03)
AD: 1q21.3 locus,HRNR, FLG;41 FLG20,42
rs471144 152454255 LCE5A (MIM 612619) AD 1.54 (1.37–1.73) 1.03 (0.94–1.14) AD: 1q21.3 locus,HRNR, FLG;41 FLG20,42
rs10888499 152532742 LCE3E (MIM 612617) AD 1.49 (1.38–1.61) 0.98 (0.93–1.04) AD: 1q21.3 locus,HRNR, FLG;41 FLG20,42
rs4112788 152551276 LCE3D (MIM 612616) psoriasis 0.97 (0.90–1.05) 1.22 (1.15–1.28) psoriasis: LCE gene cluster;17 LCE3D24
rs1581803 152592281 LCE3A (MIM 612613) psoriasis 0.97 (0.90–1.04) 1.22 (1.15–1.30) psoriasis: LCE gene cluster17
rs77199844 (del) 152757094 LCE1E (MIM 612607) [AD] 2.01 (1.72–2.35) 1.16 (1.01–1.33) AD: 1q21.3 locus,HRNR, FLG;41 FLG20,42
psoriasis: LCE gene cluster17
rs4363385 152989321 SNORA31, SPRR3 (MIM 182271),
SPRR1B (MIM 182266)
[opposing] 1.23 (1.15–1.32) 0.89 (0.85–0.94) AD: SPRR3 repeat number variant43
2p16.1 rs35741374 61072567 within lincRNA AC010733.4 psoriasis 1.09 (1.01–1.63) 1.20 (1.15–1.27) psoriasis: REL;24 NR23
2q31.2 rs62176107 179300971 exonic PRKRA and within miRNA548n
and AC009948.5
opposing 0.55 (0.46–0.65) 1.42 (1.32–1.53) –
5q31.1a rs1295686 131952222 intronic IL13 (MIM 147683) and within
AC004041.2
[opposing] 1.27 (1.17–1.38) 0.88 (0.82–0.94) AD and psoriasis: IL13;21 KIF3A, IL13;22
KIF3A, IL4, IL13-RAD50;10 multiple
effect locus RAD50/IL13;20 C5orf56
rs6596086 131995843 intronic RAD50 (MIM 604040) opposing 1.30 (1.20–1.41) 0.85 (0.8–0.91) AD and psoriasis: IL13-RAD50;10
multiple effect locus RAD50/IL1320
5q33.1 rs17728338 150478318 ANXA6 (MIM 114070) opposing 0.70 (0.59–0.84) 1.77 (1.61–1.95) psoriasis: TNIP121,42
5q33.3 rs10515778, rs7715173,
rs7719425b
158658012, 158664631,
158670938
within CTB-11I22.1 psoriasis 1.07 (0.98–1.17) 1.29 (1.21–1.38) psoriasis: 5q33.3 locus, IL12B17,21,24,44;
AD: PTTG142
rs11135056,
rs4921442b
158687281, 158694100 intronic UBLCP1 (MIM 609867) psoriasis 0.97 (0.89–1.05) 1.45 (1.35–1.56)
rs2546890 158759900 within AC008697.1 psoriasis 1.01 (0.94–1.06) 1.39 (1.32–1.47)
rs5872599 (indel) 158859989 lincRNA AC008703.1, IL12B
(MIM 161561)
psoriasis 0.82 (0.73–0.93) 1.54 (1.45–1.64)
6q21 rs9487605 111582885 intronic KIAA1919 psoriasis 1.06 (0.98–1.14) 1.27 (1.20–1.35) –
rs240993 111673714 intronic REV3L (MIM 602776) psoriasis 1.05 (0.97–1.13) 1.29 (1.22–1.36) –
rs9481169 111929862 TRAF3IP2 (MIM 607043) psoriasis 0.98 (0.86–1.11) 1.58 (1.45–1.72) psoriasis and psoriatic arthritis:
TRAF3IP224,44,45
(Continued on next page)
T
h
e
A
m
e
rica
n
Jo
u
rn
a
l
o
f
H
u
m
a
n
G
e
n
e
tics
9
6
,
1
0
4
–
1
2
0
,
Ja
n
u
a
ry
8
,
2
0
1
5
1
0
9
T
a
b
le
1
.
C
o
n
ti
n
u
e
d
C
h
r
B
a
n
d
R
e
fe
re
n
c
e
S
N
V
N
u
m
b
e
r(
s)
P
o
si
ti
o
n
(h
g
1
9
)
N
e
a
re
st
G
e
n
e
(s
)
o
r
T
ra
n
sc
ri
p
t(
s)
E
ff
e
c
t
O
b
se
rv
e
d
in
G
W
A
n
a
ly
se
s
E
st
im
a
te
d
O
d
d
s
R
a
ti
o
(9
5
%
C
I)
P
re
v
io
u
s
R
e
p
o
rt
(s
)
o
f
A
ss
o
c
ia
ti
o
n
a
t
T
h
is
L
o
c
u
s
A
D
P
so
ri
a
si
s
6
q
2
3
.2
rs
6
4
3
1
7
7
,
rs
5
8
2
7
5
7
b
1
3
8
1
9
5
6
9
3
,
1
3
8
1
9
7
8
2
4
T
N
FA
IP
3
(M
IM
6
1
0
6
6
9
)
p
so
ri
as
is
1
.0
5
(0
.9
7
–1
.1
4
)
1
.2
7
(1
.2
0
–1
.3
4
)
p
so
ri
as
is
:
T
N
FA
IP
3
2
1
,2
4
1
1
q
1
3
.5
rs
2
2
1
2
4
3
4
,
rs
7
1
2
6
4
1
8
b
7
6
2
8
1
5
9
3
,
7
6
2
9
2
5
7
3
c1
1
or
f3
0
(M
IM
6
0
8
5
7
4
)
A
D
1
.2
9
(1
.2
1
–1
.3
9
)
1
.0
5
(1
.0
0
–1
.1
1
)
A
D
:
c1
1
or
f3
0
-L
R
R
C
3
2
;1
0
,4
1
c1
1
or
f3
0
;2
2
1
1
q
1
3
lo
cu
s2
0
1
2
q
1
3
.3
rs
3
6
2
0
7
8
7
1
(d
el
)
5
6
6
8
4
4
9
6
in
tr
o
n
ic
C
S
(M
IM
1
1
8
9
5
0
)
p
so
ri
as
is
0
.9
4
(0
.8
3
–1
.0
6
)
1
.4
7
(1
.3
3
–1
.6
7
)
p
so
ri
as
is
:
1
2
q
1
3
.3
lo
cu
s,
IL
2
3
A
,
ST
A
T
2
;2
1
IL
2
3
A
2
4
rs
1
1
5
7
5
2
3
4
5
6
7
4
4
2
7
6
in
tr
o
n
ic
ST
A
T
2
(M
IM
6
0
0
5
5
6
)
p
so
ri
as
is
0
.9
0
(0
.7
9
–1
.0
2
)
1
.4
7
(1
.3
2
–1
.6
4
)
p
so
ri
as
is
:
ST
A
T
2
2
1
G
e
n
o
m
e
-w
id
e
si
g
n
ifi
ca
n
ce
is
d
e
fi
n
e
d
a
s
C
C
M
A
T
m
a
x
>
6
a
n
d
M
A
N
T
R
A
B
FD
P
<
0
.0
5
w
it
h
P
O
¼
1
/9
9
9
a
n
d
m
u
lt
in
o
m
ia
l
m
o
d
e
l
p
<
1
0

8
;
g
e
n
e
s
a
n
d
tr
a
n
sc
ri
p
ts
id
e
n
ti
fi
e
d
fr
o
m
U
C
S
C
G
e
n
o
m
e
B
ro
w
se
r
H
u
m
a
n
Fe
b
.
2
0
0
9
(G
R
C
h
3
7
/h
g
1
9
)
A
ss
e
m
b
ly
a
cc
e
ss
e
d
2
1
M
a
rc
h
2
0
1
4
;
th
is
va
ri
a
n
t
o
f
FL
G
-A
S
1
e
x
te
n
d
s
a
cr
o
ss
H
R
H
R
a
n
d
FL
G
;
R
P
1
-9
1
G
5
.3
e
x
te
n
d
s
a
cr
o
ss
C
R
N
N
;
A
C
0
0
4
0
4
1
.2
e
x
te
n
d
s
a
cr
o
ss
R
A
D
5
0
a
n
d
IL
1
3
;
C
T
B
-1
1
I2
2
.1
o
ve
rl
a
p
s
R
N
F1
4
5
.
a
1
q
2
1
.3
a
n
d
5
q
3
1
.1
w
e
re
fu
rt
h
e
r
in
ve
st
ig
a
te
d
vi
a
st
e
p
w
is
e
co
n
d
it
io
n
a
l
a
n
a
ly
si
s
(t
h
e
re
su
lt
s
a
re
sh
o
w
n
in
T
a
b
le
2
);
sq
u
a
re
b
ra
ck
e
ts
in
d
ic
a
te
re
su
lt
s
fr
o
m
th
e
u
n
iv
a
ri
a
te
a
n
a
ly
si
s
th
a
t
w
e
re
su
b
se
q
u
e
n
tl
y
a
cc
o
u
n
te
d
fo
r
b
y
o
th
e
r
n
e
a
rb
y
va
ri
a
n
ts
w
h
e
n
e
x
a
m
in
e
d
b
y
st
e
p
w
is
e
co
n
d
it
io
n
a
l
a
n
a
ly
si
s.
b
M
u
lt
ip
le
S
N
V
s
a
re
a
ss
ig
n
e
d
to
th
e
sa
m
e
LD
b
lo
ck
b
u
t
o
d
d
s
ra
ti
o
s
a
n
d
9
5
%
C
I
a
re
p
re
se
n
te
d
o
n
ly
fo
r
th
e
fi
rs
t
S
N
V
.
110 The American Journal of Human Genetics 96, 104–120, January 8reflects the importance of calcium-dependent effects in
keratinocyte differentiation.
Opposing effect loci were also identified within regions
characterized by complex patterns of LD within the EDC
(Figure S4), the cytokine cluster on 5q31.1 (Figures S4
and S5), and the MHC. These regions were therefore inves-
tigated further via conditional analysis.
Stepwise Conditional Analysis within 1q21.3 and
5q31.1 Identifies Opposing and Disease-Specific Risk
Variants
Coverage of the EDC was achieved via GWAS data
(Figure 3), whereas ImmunoChip data provided better
coverage for the cytokine cluster on 5q31.1 (Figures 4
and S5).
Within 1q21.3 we identified seven LD blocks with dis-
ease-specific or opposing signals (Figure 3A). Stepwise
conditional analysis on the four most prevalent FLG-
null mutations and variants tagging the LCE3B-LCE3C
deletion identified one AD-specific locus mapping to
FLG, a psoriasis-specific locus mapping to LCE3B-LCE3C,
and a locus with opposing effects on both diseases map-
ping to RPTN (MIM 613259)/HRNR/FLG-AS1 (Figure 3B
and Table 2). After conditioning on the four FLG-null mu-
tations and the LCE3B-LCE3C deletion, the G allele of the
lead MNM SNV rs12130219 decreases the risk for AD
(ORADcond ¼ 0.812, pADcond ¼ 0.0018) and increases the
risk for psoriasis (ORPSOcond ¼ 1.119, pPSOcond ¼ 3.68 3
104) (Table 2). Filaggrin, repetin, and hornerin are all
members of the S100 fused-type protein family and each
contribute to the cornified cell envelope, a functional
component of the epidermal barrier. Both FLG and
HRNR show reduced expression in AD51–53 whereas
RPTN shows no significant difference (Table S7). In psori-
asis HRNR expression can be downregulated53 or upregu-
lated,54 RPTN expression might be upregulated, and FLG
expression might be downregulated55 or dysregulated15
(Table S7). The function of FLG-AS1 (FLG antisense
RNA1) is currently undefined, but its proximity to FLG
and HRNR suggests a role in coordinating keratinocyte
terminal differentiation. FLG-AS1 expression is increased
in psoriasis lesional compared with nonlesional skin,
whereas in AD lesional skin, expression is reduced (Table
S7). Together, our results confirm the role of the LCE3B-
LCE3C deletion in psoriasis and support the presence of
genetic risk mechanisms for AD within the EDC in addi-
tion to the predominant effect of FLG-null mutations,
with opposing effects on psoriasis.
Conditional analysis at 5q31.1 revealed three indepen-
dent loci specifically contributing to AD risk: IL13 (MIM
147683, rs848, ORADfull ¼ 1.12, p ¼ 0.0204), KIF3A (MIM
604683, rs 2299009, ORADfull ¼ 1.16, p ¼ 4.1 3 104),
and SLC22A4 (MIM 604190)/C5orf56 (rs74458173, ORAD-
full ¼ 1.57, p ¼ 2.0 3 104) (Figure 4A, Table 2). None of
these loci showed significant effects on psoriasis. However,
a fourth independent locus has opposing effects on AD
and psoriasis. The most highly significant variant maps, 2015
AB
Figure 3. Regional Association within the Epidermal Differentiation Complex at 1q21.3
(A) Multinomial regression model with GWAS and ImmunoChip data. Seven blocks of linkage disequilibrium are indicated by curly
brackets; black circles indicate AD-specific association, red circles indicate a psoriasis-specific association, blue circles represent opposing
effects in AD and psoriasis, and green circles indicate shared effects. Vertical lines have been drawn tomark the positions of known genes
and transcripts (identified from UCSC Genome Browser, GRCh37/hg19 accessed Feb. 2009) and the horizontal dotted lines indicate
thresholds of suggestive and genome-wide significance (p ¼ 105 and 108). The horizontal gray bands at the bottom indicate the
coverage of the region by GWAS SNVs (upper row) and ImmunoChip SNVs (lower row).
(B) Conditional regional association plot of stepwise logistic regression using GWAS and ImmunoChip data. The different colored sym-
bols indicate association results after each step of analysis, as follows. Unconditioned results are shown by black dots to indicate asso-
ciation with AD and red dots to indicate association with psoriasis; blue triangles and blue crosses represent results after conditioning on
the known disease-associated variants, FLG in AD and LCE3B-LCE3C deletion in psoriasis; SNVs indicated by the same symbol are in LD
(legend continued on next page)
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to RAD50 (MIM 604040, rs6596086, ORADfull ¼ 1.17, ORP-
SOfull¼ 0.88, p¼ 6.33 107); this variant is associated with
increased risk of AD but is protective against psoriasis
(Figure 4B, Table 2).
Analysis of the MHC Confirms Multiple Psoriasis-Risk
Loci and Identifies Opposing Effects
In the extended HLA region, we took forward 23,479 SNVs
with Tmax > 4.7 or BFDP < 0.05 (PO ¼ 1/99) and 75 vari-
ables representing the classical HLA alleles obtained from
HLA imputation for multinomial modeling, of which
18,515 SNVs were classified as specific to psoriasis by
CCMA and MNM. To reduce the data set for post hoc anal-
ysis, we considered only SNVs with effect classification in
the same direction by CCMA and MNM, meeting the p <
105 threshold in MNM. Within the psoriasis-specific
markers, we excluded all tagging SNVs (r2 > 0.8 with the
lead SNV), resulting in 1,503 SNVs, including those previ-
ously reported for AD.20
The strongest and most significant association was
observed for psoriasis, a variant (rs111576655 ORPSOfull ¼
3.32, p ¼ 3.2 3 1065) tagging the well-known psoriasis-
risk allele HLA-C*06:02 (ORPSOfull ¼ 3.59, p ¼ 8.7 3
10154). Conditional analysis revealed two additional inde-
pendent loci contributing to psoriasis risk at MICA (MIM
600169, rs201374403, ORPSOfull ¼ 1.65, p ¼ 1.0 3 1026)
and HLA-A (MIM 142800, rs113573479, ORPSOfull ¼ 1.41,
p ¼ 2.7 3 1017), as well as two loci with opposing effects
at HLA-C (MIM 142840, rs1793889, ORADfull ¼ 0.6, ORPSO-
full ¼ 1.18, p ¼ 1.1 3 109) and HLA-DRB1 (MIM 142857,
rs28383201, ORADfull ¼ 0.61, ORPSOfull ¼ 1.18, p ¼ 6.5 3
109) (Figure 5, Table 3). Conditional analysis with
imputed classical alleles identified five independent HLA-
class I alleles contributing to psoriasis risk in addition to
HLA-C*06:02 and two alleles with opposing effects: HLA-
C*03:03 (ORADfull ¼ 0.71, ORPSOfull ¼ 1.27, p ¼ 2.3 3
105) and HLA-DQA1*02:01 (ORADfull ¼ 0.64, ORPSOfull ¼
1.09, p ¼ 6.0 3 108; r2 ¼ 0.405 with rs28383201)
(Table 3).
Ontology and Network Analysis of Genes Indicate
Effects in the Skin Barrier and Immune Response
Genes implicated from genome-wide and conditional ana-
lyses (identified from Tables 1, 2, and 3) were investigated
via predicted protein network and gene ontology (GO)
analysis. The results are summarized in Figure S6. The
GO term ‘‘keratinocyte differentiation’’ (GO:0030216) is
enriched in genes implicated in AD and psoriasis risk
(FDR p ¼ 4.3 3 104 in AD; p ¼ 6.9 3 104 in psoriasis;
and p ¼ 2.7 3 103 in opposing effects). The GO term
‘‘response to interferon-gamma’’ (GO:0034341) is also
significantly enriched in psoriasis (FDR p ¼ 1.9 3 103).with the lead SNV of each stepwise conditional analysis (defined as r
genes and transcripts (identified from the UCSC Genome Browser GR
cate significance thresholds of p¼ 0.005, 105, and 108. The horizon
GWAS SNVs (upper row) and ImmunoChip SNVs (lower row).
112 The American Journal of Human Genetics 96, 104–120, January 8Discussion
This genome-wide comparative analysis confirms a high
degree of genomic coincidence between AD and psoriasis,
suggesting that common molecular mechanisms are
involved. This agrees with the central role of epidermal
barrier defects and T-cell-dominated inflammation in
both diseases.48 Within the six regions of colocalization,
we demonstrate coassociated and independent disease-
specific loci. Of note, all coassociated loci display opposing
(antagonistic) effects on AD and psoriasis, in agreement
with the epidemiological observations of lower-than-
expected coincidence between these diseases in the popu-
lation.5 Within these loci, specific variants including
chromosome 2q31.2 (rs62176107), chromosome 5q33.1
(rs17728338), and within RAD50 on chromosome 5q33.3
(rs6596086) demonstrate opposing effects on risk of AD
and psoriasis. This raises the intriguing possibility that
the same biological mechanisms might act differentially
on AD versus psoriasis. However, our current data cannot
distinguish this specific opposing mechanism from the
possibility that each lead variant is in LD with other vari-
ants having opposing effects in each disease.
Themajority of the opposing effect loci are implicated in
pathways related to adaptive immunological functions,
which potentially mirrors the polarized immune mecha-
nisms.6 It might further be speculated whether the
presence of multiple opposing alleles reflects balancing
selection as a response to heterogeneity in environmental
pressures. Balancing selection is particularly common
within the extended MHC region and has been proposed
as a potential explanation for antagonistic effects at multi-
ple loci in different autoimmune diseases.56
Two of the loci displaying opposing effects (ANXA6/
TNIP1 and PRKRA) have not previously been reported in
association with psoriasis and/or AD. Formal external vali-
dation is limited by the requirement for additional inde-
pendent, population-matched GWAS data for AD and pso-
riasis, but data available from RNA sequencing and
microarray analyses provide some support for the differen-
tial expression of ANXA6/TNIP1 and PRKRA in AD and pso-
riasis, relative to normal or uninvolved skin. The lead
variant within PRKRA might mediate opposing effects in
AD and psoriasis via miRNA processing and/or cellular
response to environmental stress, and we hypothesize
that this reflects the striking differential susceptibility to
viral and bacterial skin infections observed in AD and pso-
riasis. The opposing effect of variation in ANXA6 suggests a
role for calcium-dependent effects in defining patterns of
skin inflammation.
On chromosome 1q21.3, apart from well-established
AD-associated FLG mutations and psoriasis-associated2R 0.5). Vertical lines are drawn to mark the positions of known
Ch37/hg19 accessed Feb. 2009), and horizontal dotted lines indi-
tal gray bands at the bottom indicate the coverage of the region by
, 2015
AB
Figure 4. Regional Association within the Cytokine Cluster at 5q31.1
(A) Multinomial regression model with GWAS and ImmunoChip data. Black circles indicate AD-specific association, red circles indicate
psoriasis-specific association, blue circles represent opposing effects in AD and psoriasis, and green circles indicate shared effects. Vertical
gray shading marks the positions of known genes (identified from the UCSC Genome Browser GRCh37/hg19 accessed Feb. 2009), and
horizontal dotted lines indicate suggestive and genome-wide significance thresholds (p¼ 105 and 108, respectively); results are shown
for SNVs in LD with the lead SNV (defined as r2R 0.5). The horizontal bands at the bottom indicate the coverage of the region by GWAS
SNVs (upper row) and ImmunoChip SNVs (lower row).
(B) Conditional regional association plot of the EDC bymultinomial regression of GWAS and ImmunoChip data. Different symbols indi-
cate association results after each step of analysis, as follows. Unconditioned results are shown by blue circles representing opposing ef-
fects in AD and psoriasis; black dots showAD-specific association results after conditioning on the lead SNV in RAD50 (a gene reported to
(legend continued on next page)
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deletion of LCE3B-LCE3C, FLG-AS1 is a plausible candidate
to mediate differential AD/psoriasis risk via the network of
regulatory elements coordinating gene expression.57 Natu-
ral antisense transcripts contribute to gene regulation via a
variety of transcriptional and posttranscriptional mecha-
nisms58 and include effects on human epidermal differen-
tiation.59 The proximity of FLG-AS1 to FLG and HRNR,
combined with data showing coordinated differential
expression of these genes, supports a role in control of ker-
atinocyte terminal differentiation.
On chromosome 5q31.1, antagonistic signals for AD and
psoriasis have previously been attributed to IL13.10,11,21
We here show that IL13 polymorphisms specifically influ-
ence AD risk, whereas opposing signals map to RAD50. The
Rad50 protein, a component of the MRN complex (Mre11,
Rad50, and Nbs1), is involved in DNA double-strand break
repair but has no known function directly related to AD or
psoriasis. However, RAD50 mRNA shows significantly
increased expression in psoriasis lesional skin and a trend
to reduced expression in AD lesional skin (Table S7). Of
note, RAD50 is located in the center of the Th2-cytokine
cluster and its 30 end is part of a locus control region regu-
lating expression of these cytokine genes.60 AD and psori-
asis represent opposing extremes of Th2 cell dysregulation,
and therefore we hypothesize that RAD50 polymorphisms
might exert opposing effects on AD and psoriasis through
variation in DNA repair resulting in a differential skew in
Th2 cell response.
Our dissection of the MHC locus confirms the presence
of multiple independent psoriasis-risk loci. Markers
tagging HLA-Cw*0602 generate the strongest effects,
which is in line with previous reports.17,21,24,44,61 CD8þ
T cells are increased in the epidermis of lesional psoriatic
skin, and the association of psoriasis susceptibility primar-
ily with class I HLA alleles might reflect the critical role of
psoriasis-associated (auto-)antigen presentation to patho-
genic CD8þ T cells.62 CD8þ T cells are also increased in
the epidermis of AD skin, but with strikingly different cyto-
kine profiles compared to psoriasis.63 The opposing effects
of class II HLA alleles in AD and psoriasis might represent
the differential responses to pathogenic and allergenic
peptides presented to CD4þ T cells.64 GWASs in AD by uni-
variate and multivariate models have reported association
signals in the MHC class I and II regions22,65 and two spe-
cific HLA class II haplotypes, HLA-DRB1*0701 (a protective
effect) and HLA-B*4402 (a risk effect).20 Our analysis con-
firms the association of classical HLA class II alleles with
AD, but in the conditional analysis, only HLA-DQA1*
02:01 remained, showing a significant protective effectbe associated with AD and psoriasis); black squares indicate the resid
RAD50 and IL13 (genes reported to be associated with AD); and blac
tionally conditioning on the lead SNV in KIF3A (a gene reported to be
with the lead SNV of each stepwise conditional analysis (defined as r2
(identified from the UCSCGenome Browser GRCh37/hg19 accessed F
olds of p ¼ 0.005, 105, and 108; results are shown for SNVs in LD w
bottom indicate the coverage of the region by GWAS SNVs (upper ro
114 The American Journal of Human Genetics 96, 104–120, January 8on AD and a significant opposing effect on psoriasis. A
further opposing locus mapped to HLA-C*03:03 (Table 3).
The reported observation of AD occurring within the
offspring of parents with psoriasis8 is not supported by
our findings, and the observation that both Th1-cell-domi-
nated autoimmune and Th2-cell-dominated allergic dis-
eases can show aggregation within families7 also presents
a discrepancy with our analyses. It is possible that there
are shared risk loci for AD and psoriasis that were not de-
tected in our current study because of lack of power, if
the shared effect is not strong; alternatively, there might
be hereditary risk factors associated with predisposition
to any chronic inflammatory (auto-)immune disease. It is
also possible that diagnostic misclassification occurs,
particularly in pediatric cases, where the clinical signs of
psoriasis are more difficult to distinguish from AD than is
the case in adult disease,66 or by recall bias for disease in
parents.
It is interesting to estimate the extent to which our find-
ings can explain the mutual exclusivity of AD and psoria-
sis, but an accurate assessment is hindered by the lack of
published data on the proportion of AD and psoriasis cases
where the diseases do and do not co-occur. Henseler et al.
report a 25-fold lower prevalence of AD occurring in psori-
asis cases5 and assuming a prevalence of 10% and 2% for
AD and psoriasis, respectively,3,4 we estimate that the ef-
fects at the six opposing loci listed in Tables 1, 2, and 3
would result in a reduction in prevalence of AD from
10% to 8% within the group of individuals with psoriasis.
This 2% reduction contrasts with the 25-fold reduction re-
ported by Henseler et al.,5 which is equivalent to a reduc-
tion of 9.6%, from 10% in the population to 0.4%. Our re-
sults have therefore explained approximately 21% (2/9.63
100) of the mutual exclusivity of AD and psoriasis.
Taken together, our comparative analyses of AD and pso-
riasis support a paradigm in which genetic factors deter-
mining keratinocyte differentiation and cutaneous barrier
function have particularly strong effects on AD risk,
whereas in psoriasis genetic factors influencing (auto-)anti-
gen recognition are of paramount importance. Further-
more, multiple pleiotropic loci with antagonistic effects
contribute to opposing mechanisms of adaptive immunity
in both AD and psoriasis.
The meta-analysis-inspired methodology developed in
the course of this study has demonstrated the power to
leverage additional information from GWAS and high-
density SNV data and to dissect cross-phenotype associa-
tions. AD and psoriasis are particularly well suited to the
compare/contrast approach, but this methodology willual AD-specific association after conditioning on the lead SNVs in
k triangles indicate the residual AD-specific association after addi-
associated with AD). SNVs indicated by the same symbol are in LD
R 0.5). Vertical gray shading marks the positions of known genes
eb. 2009), and horizontal dotted lines indicate significance thresh-
ith the lead SNV (defined as r2R 0.5). The horizontal bands at the
w) and ImmunoChip SNVs (lower row).
, 2015
Table 2. Conditional Analysis of the 1q21.3 and 5q31.1 Regions Showing Disease-Specific and Opposing Risk Effects in AD and Psoriasis
Data
Source Effect SNV Pos (hg19) Allele
Candidate
Genes
AD Psoriasis
poverall
a
AD Psoriasis
Poverall
aOR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
Chromosome 1q21.3
Unconditioned Analysis Conditional Analysisb
GWAS Opposing rs12130219 152162106 G/A FLG-AS1/
RPTN/HRNR
0.66
(0.60–0.73)
1.1 3 1016 1.15
(1.09–1.224)
4.0 3 106 1.2 3 1023 0.812
(0.71–0.93)
0.0018 1.119
(1.05–1.19)
3.68
3 104
2.4 3 106
GWAS AD rs12144049 152440910 C/T FLG 1.53
(1.42–1.64)
2.7 3 1030 0.98
(0.92–1.03)
0.4140 3.0 3 1030 – – – –
GWAS Psoriasis rs1581803c 152592281 G/T LCE3B/
LCE3D
0.97
(0.90–1.04)
0.4396 1.22
(1.16–1.30)
1.5 3 1012 1.6 3 1012 – – – –
GWAS Opposing rs35722864 153040505 G/GA SPRR cluster 0.81
(0.75–0.88)
1.0 3 107 1.129
(1.07–1.20)
2.1 3 105 4.8 3 1013 0.851
(0.71–0.93)
0.0019 1.074
(1.01–1.14)
0.0211 1.3 3 104
Chromosome 5q31.1
Conditional Modelsd Full Model
Ichip Opposing rs6596086 131952222 C/T RAD50 1.31
(1.22–1.41)
1.7 3 1013 0.86
(0.80–0.92)
1.7 3 105 5.7 3 1021 1.17
(1.07–1.28)
4.04 3 104 0.88
(0.81–0.96)
0.0023 6.3 3 107
Ichip AD rs848 131996500 A/C IL13 1.20
(1.10–1.30)
5.6 3 105 0.96
(0.89–1.04)
0.3375 4.14 3 105 1.12
(1.02–1.23)
0.0197 0.96
(0.88–1.05)
0.3515 0.0204
Ichip AD rs2299009 132042813 G/T IL4/KIF3A 1.14
(1.06–1.23)
7.9 3 104 0.99
(0.92–1.06)
0.7392 0.0018 1.16
(1.07–1.25)
2.03 3 104 0.99
(0.92–1.06)
0.6657 4.1 3 104
Ichip AD rs74458173 131621731 A/C SLC22A4 1.57
(1.26–1.96)
6.1 3 105 1.02
(0.80–1.30)
0.8590 2.14 3 104 1.57
(1.26–1.96)
5.71 3 105 1.02
(0.80–1.30)
0.8683 2.0 3 104
Full model incorporates the combined effects of independent SNVs identified by stepwise analyses.
apoverall represents the overall opposing signal calculated using the T12opposing statistic and derive the p value from the normal distribution.
bConditional analysis of chr1q21.3 was conditioned on FLG for AD and LCE3B/LCE3D for psoriasis.
crs1581803 tags the previously reported psoriasis SNV rs4112788 (r2 ¼ 0.995).
dStepwise conditional analysis at chr5q31.1 was carried out usingmultinomial regression models and resulted in three additional signals for AD; this table shows only independent loci (r2< 0.5) and the SNV with the strongest
association; the effect allele is underlined.
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Figure 5. Conditional Regional Association within the Major Histocompatibility Complex at 6p21–22 via GWAS and ImmunoChip
Data
Symbols indicate association results after each step of analysis, as follows. Unconditioned psoriasis-specific results are shown by red dots;
red triangles show psoriasis-specific association results after conditioning on C*06:02 (known to be strongly associated with psoriasis);
red3s indicate psoriasis-specific association after conditioning on C*06:02 andMICA; blueþs indicate the association after conditioning
on C*06:02, MICA, and HLA-A with opposing effects on AD and psoriasis; and blue squares indicate the residual association after con-
ditioning on C*06:02,MICA, HLA-A, and HLA-DRB1with opposing effects on AD and psoriasis. SNVs indicated by the same symbol are
in LD with the lead SNVof each stepwise conditional analysis (defined as r2R 0.5). Vertical shadingmarks the positions of known genes
(identified from the UCSC Genome Browser GRCh37/hg19 accessed Feb. 2009) and HLA classes; horizontal dotted lines indicate signif-
icance thresholds of p ¼ 105 and p ¼ 108; results are shown for SNVs in LD with the lead SNV (defined as r2R 0.5). The horizontal
bands at the bottom indicate the coverage of the region by GWAS SNVs (upper row) and ImmunoChip SNVs (lower row).be applicable to many other complex traits with overlap-
ping and disease-specific phenotypic features. Character-
izing shared and opposing molecular mechanisms across
complex phenotypes will expand our understanding of
biology and disease and will have implications for treat-
ment and drug discovery.Supplemental Data
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Table 3. Conditional Analysis of the MHC Region on 6p21–22 Showing Psoriasis-Specific and Opposing Risk Effects in AD and Psoriasis
Data
Source Effect SNV Pos (hg19) Allele
HLA Allele/
Candidate
Genes
Conditional Modelsa Full Model
AD Psoriasis
poverall
AD Psoriasis
poverallOR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
GWAS PSO rs111576655 31242731 A/T C*06:02 0.84
(0.74–0.95)
0.0053 4.41
(4.10–4.74)
3.1 3 10376 9.8 3 10380 1.12
(0.81–1.54)
0.5071 3.32
(2.90–3.81)
2.3 3 1069 3.2 3 1065
GWAS PSO rs201374403 31383754 T/TAG MICA 0.78
(0.7–0.88)
6.4 3 105 1.68
(1.56–1.8)
7.9 3 1048 2.2 3 1053 0.81
(0.67–0.96)
0.0174 1.65
(1.50–1.81)
1.8 3 1025 1.0 3 1026
GWAS PSO rs113573479 29842444 A/G HLA-A 0.89
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GWAS opposing rs28383201 32574869 C/G HLA-DRB1 0.59
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4.6 3 1013 1.15
(1.06–1.24)
4.5 3 104 3.3 3 1016 0.61
(0.52–0.71)
3.4 3 1010 1.18
(1.08–1.28)
1.0 3 104 6.5 3 1014
GWAS opposing rs1793889 31222181 A/G HLA-C 0.60
(0.50–0.73)
2.5 3 107 1.18
(1.07–1.31)
0.0011 1.1 3 109 0.60
(0.50–0.73)
2.5 3 107 1.18
(1.07–1.31)
0.0011 1.1 3 109
Data
Source Effect HLA Allele
HLA Allele
Frequency in
Ps/AD/Controls
Conditional Modelsa Full Model
AD Psoriasis
poverall
AD Psoriasis
poverallOR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
GWAS PSO C*06:02 0.271/0.075/0.089 0.81 (0.71–0.91) 8.48 3 104 4.28 (3.98–4.61) 2.9 3 10362 1.30 3 10368 0.97 (0.82–1.15) 0.7475 3.59 (3.26–3.95) 2.1 3 10159 8.7 3 10154
GWAS PSO A*02:01 0.28/0.227/0.239 0.95 (0.88–1.03) 0.1793 1.32 (1.24–1.40) 4.1 3 1020 1.1 3 1020 0.99 (0.90–1.08) 0.7739 1.32 (1.24–1.41) 1.8 3 1017 1.1 3 1016
GWAS PSO B*57:01 0.13/0.017/0.032 0.61 (0.46–0.80) 3.83 3 104 1.63 (1.44–1.84) 8.0 3 1015 5.8 3 1020 0.60 (0.42–0.85) 0.0039 1.58 (1.38–1.81) 3.8 3 1011 1.1 3 1013
GWAS PSO C*12:03 0.048/0.044/0.038 0.87 (0.74–1.03) 0.1169 1.74 (1.54–2.00) 5.2 3 1018 3.5 3 1019 0.86 (0.72–1.04) 0.1295 1.85 (1.62–2.11) 7.5 3 1020 1.8 3 1020
GWAS PSO B*27:05 0.032/0.02/0.025 0.80 (0.63–1.01) 0.0619 1.59 (1.37–1.86) 2.9 3 109 3.2 3 1010 0.74 (0.55–1.00) 0.0499 1.50 (1.28–1.76) 7.3 3 107 1.8 3 107
GWAS PSO A*01:01 0.221/0.154/0.166 1.03 (0.94–1.13) 0.5475 1.25 (1.17–1.35) 2.3 3 1010 1.7 3 109 1.08 (0.96–1.21) 0.2013 1.23 (1.14–1.33) 6.8 3 108 4.0 3 107
GWAS opposing C*03:03 0.037/0.025/0.038 0.66 (0.54–0.81) 9.71 3 105 1.30 (1.13–1.49) 2.5 3 104 5.9 3 108 0.71 (0.56–0.90) 0.0040 1.27 (1.10–1.47) 0.0011 2.3 3 105
GWAS opposing DQA1*02:01 0.186/0.055/0.098 0.64 (0.54–0.76) 3.44 3 107 1.09 (1.01–1.19) 0.0385 6.0 3 108 0.64 (0.54–0.76) 3.4 3 107 1.09 (1.01–1.19) 0.0385 6.0 3 108
Effect allele is underlined. Abbreviations are as follows: PSO, psoriasis; AD, atopic dermatitis. Table shows only independent loci (r2 < 0.5) and the SNV with the strongest association.
aStepwise conditional analysis was carried out with multinomial regression models and resulted in three psoriasis-specific and two opposing signals.
T
h
e
A
m
e
rica
n
Jo
u
rn
a
l
o
f
H
u
m
a
n
G
e
n
e
tics
9
6
,
1
0
4
–
1
2
0
,
Ja
n
u
a
ry
8
,
2
0
1
5
1
1
7
Health), Ludwig-Maximilians-Universita¨t, as part of LMUinnova-
tiv. The project received infrastructure support through DFG Clus-
ters of Excellence ‘‘Inflammation at Interfaces’’ (grants EXC306
and EXC306/2) and the German Federal Ministry of Education
and Research within the framework of e:Med research and funding
concept (sysINFLAME, 01ZX1306A). M.M.N. is a member of the
Cluster of Excellence ‘‘ImmunoSensation.’’ The NCRC-ADC is sup-
ported by the National Children’s Research Centre, Dublin. We
also acknowledge use of Trinity Biobank samples from the Irish
Blood Transfusion Service. This work was supported by the NIH
(R01AR042742, R01AR050511, R01AR054966, R01AR062886-01,
R01AR062382) and by the Babcock Memorial Trust. J.T.E. is sup-
ported by the Ann Arbor Veterans Affairs Hospital.
Received: September 5, 2014
Accepted: December 5, 2014
Published: January 8, 2015Web Resources
The URLs for data presented herein are as follows:
1000 Genomes, http://browser.1000genomes.org
Ensembl Genome Browser, http://www.ensembl.org/index.html
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org/
PLINK, http://pngu.mgh.harvard.edu/~purcell/plink/
R statistical software, http://www.r-project.org/
RefSeq, http://www.ncbi.nlm.nih.gov/RefSeq
STRING 9.1, http://www.string-db.org/References
1. Deckert, S., Kopkow, C., and Schmitt, J. (2014). Nonallergic co-
morbidities of atopic eczema: an overview of systematic re-
views. Allergy 69, 37–45.
2. Griffiths, C.E., and Barker, J.N. (2007). Pathogenesis and clin-
ical features of psoriasis. Lancet 370, 263–271.
3. Parisi, R., Symmons, D.P., Griffiths, C.E., and Ashcroft, D.M.;
Identification and Management of Psoriasis and Associated
ComorbidiTy (IMPACT) project team (2013). Global epidemi-
ology of psoriasis: a systematic review of incidence and preva-
lence. J. Invest. Dermatol. 133, 377–385.
4. Deckers, I.A., McLean, S., Linssen, S., Mommers, M., van
Schayck, C.P., and Sheikh, A. (2012). Investigating interna-
tional time trends in the incidence and prevalence of atopic
eczema 1990-2010: a systematic review of epidemiological
studies. PLoS ONE 7, e39803.
5. Henseler, T., and Christophers, E. (1995). Disease concomi-
tance in psoriasis. J. Am. Acad. Dermatol. 32, 982–986.
6. Eyerich, S., Onken, A.T., Weidinger, S., Franke, A., Nasorri, F.,
Pennino, D., Grosber, M., Pfab, F., Schmidt-Weber, C.B., Mem-
pel,M., et al. (2011). Mutual antagonism of Tcells causing pso-
riasis and atopic eczema. N. Engl. J. Med. 365, 231–238.
7. Hemminki, K., Li, X., Sundquist, K., and Sundquist, J. (2009).
Shared familial aggregation of susceptibility to autoimmune
diseases. Arthritis Rheum. 60, 2845–2847.
8. Maas, T., Nieuwhof, C., Passos, V.L., Robertson, C., Boonen, A.,
Landewe´, R.B., Voncken, J.W., Knottnerus, J.A., and Damoi-
seaux, J.G. (2014). Transgenerational occurrence of allergic
disease and autoimmunity: general practice-based epidemio-
logical research. Prim. Care Respir. J. 23, 14–21.118 The American Journal of Human Genetics 96, 104–120, January 89. Cookson, W.O., Ubhi, B., Lawrence, R., Abecasis, G.R., Walley,
A.J., Cox, H.E., Coleman, R., Leaves, N.I., Trembath, R.C., Mof-
fatt, M.F., and Harper, J.I. (2001). Genetic linkage of childhood
atopic dermatitis to psoriasis susceptibility loci. Nat. Genet.
27, 372–373.
10. Paternoster, L., Standl, M., Chen, C.M., Ramasamy, A., Bønne-
lykke, K., Duijts, L., Ferreira, M.A., Alves, A.C., Thyssen, J.P.,
Albrecht, E., et al.; Australian Asthma Genetics Consortium
(AAGC); Genetics of Overweight Young Adults (GOYA) Con-
sortium; EArly Genetics & Lifecourse Epidemiology (EAGLE)
Consortium (2012). Meta-analysis of genome-wide associa-
tion studies identifies three new risk loci for atopic dermatitis.
Nat. Genet. 44, 187–192.
11. Ellinghaus, D., Baurecht, H., Esparza-Gordillo, J., Rodrı´guez,
E., Matanovic, A., Marenholz, I., Hu¨bner, N., Schaarschmidt,
H., Novak, N., Michel, S., et al. (2013). High-density genotyp-
ing study identifies four new susceptibility loci for atopic
dermatitis. Nat. Genet. 45, 808–812.
12. Tsoi, L.C., Spain, S.L., Knight, J., Ellinghaus, E., Stuart, P.E.,
Capon, F., Ding, J., Li, Y., Tejasvi, T., Gudjonsson, J.E., et al.;
Collaborative Association Study of Psoriasis (CASP); Genetic
Analysis of Psoriasis Consortium; Psoriasis Association Ge-
netics Extension; Wellcome Trust Case Control Consortium
2 (2012). Identification of 15 new psoriasis susceptibility loci
highlights the role of innate immunity. Nat. Genet. 44,
1341–1348.
13. Palmer, C.N., Irvine, A.D., Terron-Kwiatkowski, A., Zhao, Y.,
Liao, H., Lee, S.P., Goudie, D.R., Sandilands, A., Campbell,
L.E., Smith, F.J., et al. (2006). Common loss-of-function
variants of the epidermal barrier protein filaggrin are a major
predisposing factor for atopic dermatitis. Nat. Genet. 38,
441–446.
14. Rodrı´guez, E., Baurecht, H., Herberich, E., Wagenpfeil, S.,
Brown, S.J., Cordell, H.J., Irvine, A.D., and Weidinger, S.
(2009). Meta-analysis of filaggrin polymorphisms in eczema
and asthma: robust risk factors in atopic disease. J. Allergy
Clin. Immunol. 123, 1361–1370, e7.
15. Hu¨ffmeier, U., Traupe, H., Oji, V., Lascorz, J., Sta¨nder, M.,
Lohmann, J., Wendler, J., Burkhardt, H., and Reis, A.
(2007). Loss-of-function variants of the filaggrin gene are
not major susceptibility factors for psoriasis vulgaris or psori-
atic arthritis in German patients. J. Invest. Dermatol. 127,
1367–1370.
16. Zhao, Y., Terron-Kwiatkowski, A., Liao, H., Lee, S.P., Allen,
M.H., Hull, P.R., Campbell, L.E., Trembath, R.C., Capon, F.,
Griffiths, C.E., et al. (2007). Filaggrin null alleles are not asso-
ciated with psoriasis. J. Invest. Dermatol. 127, 1878–1882.
17. Zhang, X.J., Huang, W., Yang, S., Sun, L.D., Zhang, F.Y., Zhu,
Q.X., Zhang, F.R., Zhang, C., Du, W.H., Pu, X.M., et al.
(2009). Psoriasis genome-wide association study identifies sus-
ceptibility variants within LCE gene cluster at 1q21. Nat.
Genet. 41, 205–210.
18. de Cid, R., Riveira-Munoz, E., Zeeuwen, P.L., Robarge, J., Liao,
W., Dannhauser, E.N., Giardina, E., Stuart, P.E., Nair, R.,
Helms, C., et al. (2009). Deletion of the late cornified envelope
LCE3B and LCE3C genes as a susceptibility factor for psoriasis.
Nat. Genet. 41, 211–215.
19. Bergboer, J.G., Zeeuwen, P.L., Irvine, A.D., Weidinger, S., Giar-
dina, E., Novelli, G., Den Heijer, M., Rodriguez, E., Illig, T.,
Riveira-Munoz, E., et al. (2010). Deletion of Late Cornified En-
velope 3B and 3C genes is not associated with atopic derma-
titis. J. Invest. Dermatol. 130, 2057–2061., 2015
20. Weidinger, S., Willis-Owen, S.A., Kamatani, Y., Baurecht, H.,
Morar, N., Liang, L., Edser, P., Street, T., Rodriguez, E., O’Re-
gan, G.M., et al. (2013). A genome-wide association study of
atopic dermatitis identifies loci with overlapping effects on
asthma and psoriasis. Hum. Mol. Genet. 22, 4841–4856.
21. Nair, R.P., Duffin, K.C., Helms, C., Ding, J., Stuart, P.E., Gold-
gar, D., Gudjonsson, J.E., Li, Y., Tejasvi, T., Feng, B.J., et al.;
Collaborative Association Study of Psoriasis (2009).
Genome-wide scan reveals association of psoriasis with IL-23
and NF-kappaB pathways. Nat. Genet. 41, 199–204.
22. Hirota, T., Takahashi, A., Kubo, M., Tsunoda, T., Tomita, K., Sa-
kashita, M., Yamada, T., Fujieda, S., Tanaka, S., Doi, S., et al.
(2012). Genome-wide association study identifies eight new
susceptibility loci for atopic dermatitis in the Japanese popu-
lation. Nat. Genet. 44, 1222–1226.
23. Stuart, P.E., Nair, R.P., Ellinghaus, E., Ding, J., Tejasvi, T., Gud-
jonsson, J.E., Li, Y., Weidinger, S., Eberlein, B., Gieger, C., et al.
(2010). Genome-wide association analysis identifies three pso-
riasis susceptibility loci. Nat. Genet. 42, 1000–1004.
24. Strange, A., Capon, F., Spencer, C.C., Knight, J., Weale, M.E.,
Allen, M.H., Barton, A., Band, G., Bellenguez, C., Bergboer,
J.G., et al.; Genetic Analysis of Psoriasis Consortium & the
Wellcome Trust Case Control Consortium 2 (2010). A
genome-wide association study identifies new psoriasis sus-
ceptibility loci and an interaction between HLA-C and
ERAP1. Nat. Genet. 42, 985–990.
25. Williams, H.C., Burney, P.G., Pembroke, A.C., and Hay, R.J.
(1994). The U.K. Working Party’s Diagnostic Criteria for
Atopic Dermatitis. III. Independent hospital validation. Br. J.
Dermatol. 131, 406–416.
26. Krawczak, M., Nikolaus, S., von Eberstein, H., Croucher, P.J., El
Mokhtari, N.E., and Schreiber, S. (2006). PopGen: population-
based recruitment of patients and controls for the analysis of
complex genotype-phenotype relationships. Community
Genet. 9, 55–61.
27. Wichmann, H.E., Gieger, C., and Illig, T.; MONICA/KORA
Study Group (2005). KORA-gen—resource for population ge-
netics, controls and a broad spectrum of disease phenotypes.
Gesundheitswesen 67 (1), S26–S30.
28. Weiland, S.K., von Mutius, E., Hirsch, T., Duhme, H., Fritzsch,
C., Werner, B., Hu¨sing, A., Stender, M., Renz, H., Leupold, W.,
and Keil, U. (1999). Prevalence of respiratory and atopic disor-
ders among children in the East and West of Germany five
years after unification. Eur. Respir. J. 14, 862–870.
29. O’Donovan, M.C., Craddock, N., Norton, N., Williams, H.,
Peirce, T., Moskvina, V., Nikolov, I., Hamshere, M., Carroll,
L., Georgieva, L., et al.; Molecular Genetics of Schizophrenia
Collaboration (2008). Identification of loci associated with
schizophrenia by genome-wide association and follow-up.
Nat. Genet. 40, 1053–1055.
30. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira,
M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly,
M.J., and Sham, P.C. (2007). PLINK: a tool set for whole-
genome association and population-based linkage analyses.
Am. J. Hum. Genet. 81, 559–575.
31. Delaneau, O., Marchini, J., and Zagury, J.F. (2012). A linear
complexity phasing method for thousands of genomes. Nat.
Methods 9, 179–181.
32. Marchini, J., Howie, B., Myers, S., McVean, G., and Donnelly,
P. (2007). A new multipoint method for genome-wide associ-
ation studies by imputation of genotypes. Nat. Genet. 39,
906–913.The Amer33. Abecasis, G.R., Auton, A., Brooks, L.D., DePristo, M.A., Dur-
bin, R.M., Handsaker, R.E., Kang, H.M., Marth, G.T., and
McVean, G.A.; 1000 Genomes Project Consortium (2012).
An integrated map of genetic variation from 1,092 human ge-
nomes. Nature 491, 56–65.
34. Dilthey, A.T., Moutsianas, L., Leslie, S., and McVean, G.
(2011). HLA*IMP—an integrated framework for imputing
classical HLA alleles from SNP genotypes. Bioinformatics 27,
968–972.
35. Leslie, S., Donnelly, P., and McVean, G. (2008). A statistical
method for predicting classical HLA alleles from SNP data.
Am. J. Hum. Genet. 82, 48–56.
36. Bhattacharjee, S., Rajaraman, P., Jacobs, K.B., Wheeler,
W.A., Melin, B.S., Hartge, P., Yeager, M., Chung, C.C., Cha-
nock, S.J., and Chatterjee, N.; GliomaScan Consortium
(2012). A subset-based approach improves power and inter-
pretation for the combined analysis of genetic association
studies of heterogeneous traits. Am. J. Hum. Genet. 90,
821–835.
37. Morris, A.P. (2011). Transethnic meta-analysis of genomewide
association studies. Genet. Epidemiol. 35, 809–822.
38. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast and
efficient meta-analysis of genomewide association scans. Bio-
informatics 26, 2190–2191.
39. Wakefield, J. (2009). Bayes factors for genome-wide associa-
tion studies: comparison with P-values. Genet. Epidemiol.
33, 79–86.
40. Liu, Y., Helms, C., Liao, W., Zaba, L.C., Duan, S., Gardner, J.,
Wise, C., Miner, A., Malloy, M.J., Pullinger, C.R., et al.
(2008). A genome-wide association study of psoriasis and pso-
riatic arthritis identifies new disease loci. PLoS Genet. 4,
e1000041.
41. Esparza-Gordillo, J., Weidinger, S., Fo¨lster-Holst, R., Bauer-
feind, A., Ruschendorf, F., Patone, G., Rohde, K., Marenholz,
I., Schulz, F., Kerscher, T., et al. (2009). A common variant
on chromosome 11q13 is associated with atopic dermatitis.
Nat. Genet. 41, 596–601.
42. Sun, L.D., Xiao, F.L., Li, Y., Zhou, W.M., Tang, H.Y., Tang, X.F.,
Zhang, H., Schaarschmidt, H., Zuo, X.B., Foelster-Holst, R.,
et al. (2011). Genome-wide association study identifies two
new susceptibility loci for atopic dermatitis in the Chinese
Han population. Nat. Genet. 43, 690–694.
43. Marenholz, I., Rivera, V.A., Esparza-Gordillo, J., Bauerfeind, A.,
Lee-Kirsch, M.A., Ciechanowicz, A., Kurek, M., Piskackova, T.,
Macek, M., and Lee, Y.A. (2011). Association screening in the
Epidermal Differentiation Complex (EDC) identifies an SPRR3
repeat number variant as a risk factor for eczema. J. Invest.
Dermatol. 131, 1644–1649.
44. Ellinghaus, E., Ellinghaus, D., Stuart, P.E., Nair, R.P., Debrus, S.,
Raelson, J.V., Belouchi, M., Fournier, H., Reinhard, C., Ding, J.,
et al. (2010). Genome-wide association study identifies a
psoriasis susceptibility locus at TRAF3IP2. Nat. Genet. 42,
991–995.
45. Hu¨ffmeier, U., Uebe, S., Ekici, A.B., Bowes, J., Giardina, E., Ko-
rendowych, E., Juneblad, K., Apel, M., McManus, R., Ho, P.,
et al. (2010). Common variants at TRAF3IP2 are associated
with susceptibility to psoriatic arthritis and psoriasis. Nat.
Genet. 42, 996–999.
46. Patel, C.V., Handy, I., Goldsmith, T., and Patel, R.C. (2000).
PACT, a stress-modulated cellular activator of interferon-
induced double-stranded RNA-activated protein kinase, PKR.
J. Biol. Chem. 275, 37993–37998.ican Journal of Human Genetics 96, 104–120, January 8, 2015 119
47. Kok, K.H., Lui, P.Y., Ng, M.H., Siu, K.L., Au, S.W., and Jin, D.Y.
(2011). The double-stranded RNA-binding protein PACT func-
tions as a cellular activator of RIG-I to facilitate innate anti-
viral response. Cell Host Microbe 9, 299–309.
48. Guttman-Yassky, E., Nograles, K.E., and Krueger, J.G. (2011).
Contrasting pathogenesis of atopic dermatitis and psoria-
sis—part I: clinical and pathologic concepts. J. Allergy Clin.
Immunol. 127, 1110–1118.
49. Pruim, R.J., Welch, R.P., Sanna, S., Teslovich, T.M., Chines,
P.S., Gliedt, T.P., Boehnke, M., Abecasis, G.R., and Willer, C.J.
(2010). LocusZoom: regional visualization of genome-wide as-
sociation scan results. Bioinformatics 26, 2336–2337.
50. Elder, J.T., Bruce, A.T., Gudjonsson, J.E., Johnston, A., Stuart,
P.E., Tejasvi, T., Voorhees, J.J., Abecasis, G.R., and Nair, R.P.
(2010). Molecular dissection of psoriasis: integrating genetics
and biology. J. Invest. Dermatol. 130, 1213–1226.
51. Henry, J., Hsu, C.Y., Haftek, M., Nachat, R., de Koning, H.D.,
Gardinal-Galera, I., Hitomi, K., Balica, S., Jean-Decoster, C.,
Schmitt, A.M., et al. (2011). Hornerin is a component of the
epidermal cornified cell envelopes. FASEB J. 25, 1567–1576.
52. Guttman-Yassky, E., Sua´rez-Farin˜as, M., Chiricozzi, A., Nog-
rales, K.E., Shemer, A., Fuentes-Duculan, J., Cardinale, I.,
Lin, P., Bergman, R., Bowcock, A.M., and Krueger, J.G.
(2009). Broad defects in epidermal cornification in atopic
dermatitis identified through genomic analysis. J. Allergy
Clin. Immunol. 124, 1235–1244, e58.
53. Wu, Z., Hansmann, B., Meyer-Hoffert, U., Gla¨ser, R., and
Schro¨der, J.M. (2009). Molecular identification and expression
analysis of filaggrin-2, a member of the S100 fused-type pro-
tein family. PLoS ONE 4, e5227.
54. Takaishi, M., Makino, T., Morohashi, M., and Huh, N.H.
(2005). Identification of human hornerin and its expression
in regenerating and psoriatic skin. J. Biol. Chem. 280, 4696–
4703.
55. Kim, B.E., Howell, M.D., Guttman-Yassky, E., Gilleaudeau,
P.M., Cardinale, I.R., Boguniewicz, M., Krueger, J.G., and
Leung, D.Y. (2011). TNF-a downregulates filaggrin and loricrin
through c-JunN-terminal kinase: role for TNF-a antagonists to
improve skin barrier. J. Invest. Dermatol. 131, 1272–1279.
56. Wang, K., Baldassano, R., Zhang, H., Qu, H.Q., Imielinski,
M., Kugathasan, S., Annese, V., Dubinsky, M., Rotter, J.I.,
Russell, R.K., et al. (2010). Comparative genetic analysis of
inflammatory bowel disease and type 1 diabetes implicates
multiple loci with opposite effects. Hum. Mol. Genet. 19,
2059–2067.120 The American Journal of Human Genetics 96, 104–120, January 857. de Guzman Strong, C., Conlan, S., Deming, C.B., Cheng, J.,
Sears, K.E., and Segre, J.A. (2010). A milieu of regulatory ele-
ments in the epidermal differentiation complex syntenic
block: implications for atopic dermatitis and psoriasis. Hum.
Mol. Genet. 19, 1453–1460.
58. Faghihi, M.A., and Wahlestedt, C. (2009). Regulatory roles of
natural antisense transcripts. Nat. Rev. Mol. Cell Biol. 10,
637–643.
59. Kretz, M., Siprashvili, Z., Chu, C., Webster, D.E., Zehnder, A.,
Qu, K., Lee, C.S., Flockhart, R.J., Groff, A.F., Chow, J., et al.
(2013). Control of somatic tissue differentiation by the long
non-coding RNA TINCR. Nature 493, 231–235.
60. Lee, G.R., Spilianakis, C.G., and Flavell, R.A. (2005). Hypersen-
sitive site 7 of the TH2 locus control region is essential for
expressing TH2 cytokine genes and for long-range intrachro-
mosomal interactions. Nat. Immunol. 6, 42–48.
61. Knight, J., Spain, S.L., Capon, F., Hayday, A., Nestle, F.O., Clop,
A., Barker, J.N., Weale, M.E., and Trembath, R.C.; Wellcome
Trust Case Control Consortium; Genetic Analysis of Psoriasis
Consortium; I-chip for Psoriasis Consortium (2012). Condi-
tional analysis identifies three novel major histocompatibility
complex loci associated with psoriasis. Hum. Mol. Genet. 21,
5185–5192.
62. Gunderson, A.J., Mohammed, J., Horvath, F.J., Podolsky, M.A.,
Anderson, C.R., and Glick, A.B. (2013). CD8(þ) T cells mediate
RAS-induced psoriasis-like skin inflammation through IFN-g.
J. Invest. Dermatol. 133, 955–963.
63. Hijnen, D., Knol, E.F., Gent, Y.Y., Giovannone, B., Beijn, S.J.,
Kupper, T.S., Bruijnzeel-Koomen, C.A., and Clark, R.A.
(2013). CD8(þ) T cells in the lesional skin of atopic dermatitis
and psoriasis patients are an important source of IFN-g, IL-13,
IL-17, and IL-22. J. Invest. Dermatol. 133, 973–979.
64. Mangalam, A.K., Taneja, V., and David, C.S. (2013). HLA class
II molecules influence susceptibility versus protection in in-
flammatory diseases by determining the cytokine profile.
J. Immunol. 190, 513–518.
65. Okada, Y., Han, B., Tsoi, L.C., Stuart, P.E., Ellinghaus, E., Te-
jasvi, T., Chandran, V., Pellett, F., Pollock, R., Bowcock, A.M.,
et al. (2014). Fine mapping major histocompatibility complex
associations in psoriasis and its clinical subtypes. Am. J. Hum.
Genet. 95, 162–172.
66. Kapila, S., Hong, E., and Fischer, G. (2012). A comparative
study of childhood psoriasis and atopic dermatitis and greater
understanding of the overlapping condition, psoriasis-derma-
titis. Australas. J. Dermatol. 53, 98–105., 2015
